Anavex Life Sciences Corp (AVXL)

[frrol]

You not have a "molecular biology understanding of its unique activation of S1". There is not much molecular biology evidence of it being a unique agonist. And when actually reading pre-clinical evidence, you see that it is in fact not unique in any discernible manner. Not yet. Hopefully it is unique - most importantly clinically. Which is very different, far more important, what we are trying to determine, and having some success so far.